Global Biosimilars Market and Forecast (By Product Type, Applications, Country Wise and Companies) to 2021 and Biosimilars Approved and Pipeline Analysis

Publisher Name :
Date: 03-Oct-2016
No. of pages: 177

The biosimilars are poised to capture an unprecedented position in the biopharmaceutical industry driven by an increased extent of adoption and growing investment and deal making activity globally. The global biosimilars market is predicted to cross US$ 25 Billion mark by 2020.  With the continuous increasing demand for biologics, manufacturers are looking for novel strategies that will help them attain maximum returns on investment. Biosimilars are seen as the key weapon to curbing soaring healthcare costs globally. The major factor that is driving the market for biosimilars industry is the fact that major biologics are nearing the patent cliff. Further, the lower cost of these drugs as compared to the patented biologics, the increasing encumbrance to curb healthcare costs globally, increasing nationwide government initiatives, and the strong pipeline for the biosimilar drugs is expected to fuel the biosimilars industry. On the other hand, high manufacturing complexities and costs, stringent regulatory requirements in countries and operational challenges are restricting the growth of the biosimilars market.

Key Highlights of the Report

Biosimilars Market - By Product Type


  • The erythropoietin (EPO) captures maximum share of the global biosmilars market.

  • The Granulocyte- Colony Stimulating Factor (G-CSF) market is expected to cross US$ 6 Billion mark by 2021.

  • The Human Growth Hormone (HGH) biosimilars market is expected to grow with a double digit CAGR during the period 2016 - 2021.

  • The monoclonal antibody is expected to show the highest growth rate during the period 2016 - 2021.

  • The insulin and interferon product segment each accounted for single digit share of the global biosimilars market respectively in 2015.


Biosimilars Market - By Applications


  • Among various application segments of biosimilar market, blood disorders and oncology together accounted for over 55% share of the global biosimilars market in 2015.

  • Growth hormone deficiencies application is expected to show double digit CAGR during the period 2016 - 2021.

  • The chronic and autoimmune disorders captured XX% share of the biosmilars market in 2015.


Biosimilars Market - By Country Wise


  • The market for biosimilars in the U.S. has gained momentum after the launch of Novartis’ Zarxio in September 2015.

  • In the European countries, Germany is at the forefront with around XX% share of the biosimilars market in 2015 followed by France with XX% share in the same year.

  • China accounted for XX% share of the global biosimilar market in 2015.

  • India is seen as a key player in the biosimilar space with an exceptionally high number of approvals granted in the last decade compared to the global average.

  • South Korea captured XX% of the global biosimilar market in 2015 being closely followed by Brazil with XX% share in the same year.


The report “Global Biosimilars Market and Forecast (By Product Type, Applications, Country Wise & Companies) to 2021 and Biosimilars Approved & Pipeline Analysis” provides a comprehensive assessment of the fast-evolving, high-growth Global Biosimilars market.

This 177 Page report with 74 Figures and 27 Tables is analyzed from 6 viewpoints:


  • Global Biosimilars Market and Forecast - By Product Type

  • Global Biosimilars Market and Forecast - By Applications

  • Global Biosimilars Market and Forecast - By Country Wise

  • Global Biosimilars Company - Profile, Revenue, Approved and Pipeline Biosimilars Analysis

  • Country with Biosimilar Guideline and Published Year

  • Global Biosimilars Market - Driving Factors and Challenges


Global Biosimilars Market and Forecast - 7 Product Types Covered


  • Erythropoietin (EPO)

  • Human Growth Hormone (HGH)

  • Granulocyte- Colony Stimulating Factor (G-CSF)

  • Monoclonal Antibody (mAb)

  • Insulin

  • Interferon (IFN)

  • Others


Global Biosimilars Market and Forecast - 5 Applications Covered


  • Oncology

  • Blood Disorders

  • Growth Hormone Deficiencies

  • Chronic and Autoimmune Disorders

  • Other Applications


Global Biosimilars Market and Forecast - 16 Countries Covered


  • United States

  • Canada

  • Argentina

  • Germany

  • France

  • Italy

  • Spain

  • United Kingdom

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Brazil

  • Mexico

  • Rest of the World


Global Biosimilars Company Analysis - 13 Companies Covered


  • Biocad

  • Celltrion Inc.

  • Dong-A Socio Group

  • Pfizer Inc.

  • Intas Pharmaceuticals Ltd.

  • Sandoz International GmbH - A Novartis Company

  • Stada Arzneimittel AG

  • Teva Pharmaceutical Industries Ltd

  • Amgen Inc.

  • Biocon

  • Dr. Reddy’s Laboratories

  • Mylan

  • Merck KGaA


Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government And NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries And Local Councils and a large number of Paid Databases.

Global Biosimilars Market and Forecast (By Product Type, Applications, Country Wise and Companies) to 2021 and Biosimilars Approved and Pipeline Analysis

Table of Contents

1. Executive Summary

2. Global Biosimilars Market and Forecast to 2021

3. Global Biosimilars Market Share and Forecast to 2021
3.1 Global Biosimilars Market Share and Forecast - By Product Type
3.2 Global Biosimilars Market Share and Forecast - By Applications
3.3 Global Biosimilars Market Share and Forecast - By Country Wise

4. Global Biosimilars Market and Forecast - By Product Type
4.1 Erythropoietin (EPO) Biosimilars Market and Forecast
4.2 Human Growth Hormone (HGH) Biosimilars Market and Forecast
4.3 Granulocyte - Colony Stimulating Factor (G-CSF) Biosimilars Market and Forecast
4.4 Monoclonal Antibody (mAb) Biosimilars Market and Forecast
4.5 Insulin Biosimilars Market and Forecast
4.6 Interferon (IFN) Biosimilars Market and Forecast
4.7 Others Biosimilars Market and Forecast

5. Global Biosimilars Market and Forecast - By Applications
5.1 Oncology Biosimilars Market and Forecast
5.2 Blood Disorders Biosimilars Market and Forecast
5.3 Growth Hormone Deficiencies Biosimilars Market and Forecast
5.4 Chronic and Autoimmune Disorders Biosimilars Market and Forecast
5.5 Other Applications Biosimilars Market and Forecast

6. Global Biosimilars Market and Forecast - By Country Wise
6.1 United States Biosimilars Market and Forecast
6.2 Canada Biosimilars Market and Forecast
6.3 Argentina Biosimilars Market and Forecast
6.4 Germany Biosimilars Market and Forecast
6.4.1 Reimbursement of Biosimilars in Germany
6.5 France Biosimilars Market and Forecast
6.5.1 Reimbursement of Biosimilars in France
6.6 Italy Biosimilars Market and Forecast
6.6.1 Pricing and Reimbursement of Biosimilars in Italy
6.7 Spain Biosimilars Market and Forecast
6.8 United Kingdom Biosimilars Market and Forecast
6.8.1 Reimbursement of Biosimilars in United Kingdom
6.9 China Biosimilars Market and Forecast
6.10 Japan Biosimilars Market and Forecast
6.11 India Biosimilars Market and Forecast
6.12 South Korea Biosimilars Market and Forecast
6.13 Australia Biosimilars Market and Forecast
6.14 Brazil Biosimilars Market and Forecast
6.15 Mexico Biosimilars Market and Forecast
6.16 Rest of the World Biosimilars Market and Forecast

7. Global Biosimilars Company - Profile, Revenue, Approved and Pipeline Biosimilars Analysis
7.1 Biocad
7.1.1 Company Profile
7.1.2 Biocad - Major Biosimilars Approved for Marketing
7.1.3 Biocad - Major Biosimilars in Pipeline
7.2 Celltrion Inc.
7.2.1 Company Profile
7.2.2 Celltrion Inc. - Annual Revenue (2013 - 2015)
7.2.3 Celltrion Inc. - Major Biosimilars Approved for Marketing
7.2.4 Celltrion Inc.- Major Biosimilars in Pipeline
7.3 Dong-A Socio Group
7.3.1 Company Profile
7.3.2 Dong-A Socio Group - Annual Revenue (2014 - 2015)
7.3.3 Dong-A Socio Group - Major Biosimilars in Pipeline
7.4 Pfizer Inc.
7.4.1 Company Profile
7.4.2 Pfizer Inc. - Annual Revenue (2011 - 2015)
7.4.3 Pfizer Inc. - Major Biosimilars Approved for Marketing
7.4.4 Pfizer Inc.- Major Biosimilars in Pipeline
7.5 Intas Pharmaceuticals Ltd.
7.5.1 Company Profile
7.5.2 Intas Pharmaceuticals Ltd. - Annual Revenue (2011 - 2015)
7.5.3 Intas Pharmaceuticals Ltd. - Major Biosimilars Approved for Marketing
7.5.4 Intas Pharmaceuticals Ltd. - Major Biosimilars in Pipeline
7.6 Sandoz International GmbH - A Novartis Company
7.6.1 Company Profile
7.6.2 Sandoz International GmbH - Annual Revenue (2012 - 2015)
7.6.3 Sandoz International GmbH - Major Biosimilars Approved for Marketing
7.6.4 Sandoz International GmbH - Major Biosimilars in Pipeline
7.7 Stada Arzneimittel AG
7.7.1 Company Profile
7.7.2 Stada Arzneimittel AG - Annual Revenue (2011 - 2015)
7.7.3 Stada Arzneimittel AG - Major Biosimilars Approved for Marketing
7.7.4 Stada Arzneimittel AG - Major Biosimilars in Pipeline
7.8 Teva Pharmaceutical Industries Ltd.
7.8.1 Company Profile
7.8.2 Teva Pharmaceutical Industries Ltd. - Annual Revenue (2011 - 2015)
7.8.3 Teva Pharmaceutical Industries Ltd. - Major Biosimilars Approved for Marketing
7.9 Amgen Inc.
7.9.1 Company Profile
7.9.2 Amgen Inc. - Annual Revenue (2011 - 2015)
7.9.3 Amgen Inc. - Major Biosimilars in Pipeline
7.10 Biocon
7.10.1 Company Profile
7.10.2 Biocon - Annual Revenue (2011 - 2015)
7.10.3 Biocon - Major Biosimilars Approved for Marketing
7.10.4 Biocon - Major Biosimilars in Pipeline"
7.11 Dr. Reddy’s Laboratories
7.11.1 Company Profile
7.11.2 Dr. Reddy’s Laboratories - Major Biosimilars Approved for Marketing
7.11.3 Dr. Reddy’s Laboratories - Major Biosimilars in Pipeline
7.12 Mylan
7.12.1 Company Profile
7.12.2 Mylan - Annual Revenue (2011 - 2015)
7.12.3 Mylan - Major Biosimilars in Pipeline
7.13 Merck KGaA
7.13.1 Company Profile
7.13.2 Merck KGaA - Annual Revenue (2013 - 2014)
7.13.3 Merck KGaA - Major Biosimilars in Pipeline

8. Biosimilars Approved in Europe

9. Country with Biosimilar Guideline and Published Year

10. Global Biosimilars Market - Driving Factors
10.1 Several Blockbuster Biologics Losing Patent Protection Over the Next Decade
10.2 Growing Geriatric Population and Rising Incidences of Chronic Diseases
10.3 Entry of Biosimilars in the US Market
10.4 Ability to Curb Healthcare Cost
10.5 Clash of Global Titans Brewing in Europe and Emerging Markets
10.6 Drug Delivery Device Companies Hit the Sweet Spot
10.7 Government Initiatives
10.7.1 Initiatives Taken by Government in Various Countries

11. Global Biosimilars Market - Challenges
11.1 Regulatory Issues
11.2 Operational Challenges for Biosimilars
11.3 Biosimilars Manufacturing Challenges

List of Tables

Table 3-1: By Product Type - Global Biosimilars Market Share (Percent), 2013 - 2015
Table 3-2: By Product Type - Forecast for Global Biosimilars Market Share (Percent), 2016 - 2021
Table 3-3: Country Wise -  Biosimilars Market Share (Percent), 2014 - 2015
Table 3-4: Country Wise - Forecast for Biosimilars Market Share (Percent), 2016 - 2021
Table 6-1: Australia: Biosimilar Medicines Approved and Listed on the Pharmaceutical Benefits Scheme
Table 7-1: Biocad - Major Biosimilars Approved for Marketing
Table 7-2: Biocad - Major Biosimilars in Pipeline
Table 7-3: Celltrion Inc. - Major Biosimilars Approved for Marketing
Table 7-4: Celltrion Inc.- Major Biosimilars in Pipeline
Table 7-5: Dong-A Socio Group - Major Biosimilars in Pipeline
Table 7-6: Pfizer Inc. - Major Biosimilars Approved for Marketing
Table 7-7: Pfizer Inc.- Major Biosimilars in Pipeline
Table 7-8: Intas Pharmaceuticals Ltd. - Major Biosimilars Approved for Marketing
Table 7-9: Sandoz International GmbH - Major Biosimilars Approved for Marketing
Table 7-10: Sandoz International GmbH - Major Biosimilars in Pipeline
Table 7-11: Stada Arzneimittel AG - Major Biosimilars Approved for Marketing
Table 7-12: Stada Arzneimittel AG - Major Biosimilars in Pipeline
Table 7-13: Teva Pharmaceutical Industries Ltd. - Major Biosimilars Approved for Marketing
Table 7-14: Amgen Inc. - Major Biosimilars in Pipeline (Pivotal Trials Phase 3)
Table 7-15: Amgen Inc. - Major Biosimilars in Pipeline
Table 7-16: Biocon - Major Biosimilars Approved for Marketing
Table 7-17: Biocon - Major Biosimilars in Pipeline
Table 7-18: Dr. Reddy’s Laboratories - Major Biosimilars Approved for Marketing
Table 7-19: Merck KGaA - Major Biosimilars in Pipeline
Table 8-1: List of EMA Approved Biosimilars - Till May 2016
Table 9-1: List of Countries with Biosimilar Guideline and Published Year
Table 10-1: Europe and US: Major biological Patent Expiries, 2010 - 2020

List of Figures

Figure 2-1: Global - Biosimilars Market (Million US$), 2008 - 2015
Figure 2-2: Global - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 3-1: By Applications - Global Biosimilars Market Share (Percent), 2014 - 2015
Figure 3-2: By Applications - Forecast for Global Biosimilars Market Share (Percent), 2016 - 2021
Figure 4-1: Global - Erythropoietin (EPO) Biosimilars Market (Million US$), 2008 - 2015
Figure 4-2: Global - Forecast for Erythropoietin (EPO) Biosimilars Market (Million US$), 2016 - 2021
Figure 4-3: Global - Human Growth Hormone (HGH) Biosimilars Market (Million US$), 2008 - 2015
Figure 4-4: Global - Forecast for Human Growth Hormone (HGH) Biosimilars Market (Million US$), 2016 - 2021
Figure 4-5: Global - Granulocyte - Colony Stimulating Factor (G-CSF) Biosimilars Market (Million US$), 2009 - 2015
Figure 4-6: Global - Forecast for Granulocyte - Colony Stimulating Factor (G-CSF) Biosimilars Market (Million US$), 2016 - 2021
Figure 4-7: Global - Monoclonal Antibody (mAb) Biosimilars Market (Million US$), 2013 - 2015
Figure 4-8: Global - Forecast for Monoclonal Antibody (mAb) Biosimilars Market (Million US$), 2016 - 2021
Figure 4-9: Global - Insulin Biosimilars Market (Million US$), 2013 - 2015
Figure 4-10: Global - Forecast for Insulin Biosimilars Market (Million US$), 2016 - 2021
Figure 4-11: Global - Interferon (IFN) Biosimilars Market (Million US$), 2014 - 2015
Figure 4-12: Global - Forecast for Interferon (IFN) Biosimilars Market (Million US$), 2016 - 2021
Figure 4-13: Global - Others Biosimilars Market (Million US$), 2013 - 2015
Figure 4-14: Global - Forecast for Others Biosimilars Market (Million US$), 2016 - 2021
Figure 5-1: Global - Oncology Biosimilars Market (Million US$), 2014 - 2015
Figure 5-2: Global - Forecast for Oncology Biosimilars Market (Million US$), 2016 - 2021
Figure 5-3: Global - Blood Disorders Biosimilars Market (Million US$), 2014 - 2015
Figure 5-4: Global - Forecast for Blood Disorders Biosimilars Market (Million US$), 2016 - 2021
Figure 5-5: Global - Growth Hormone Deficiencies Biosimilars Market (Million US$), 2014 - 2015
Figure 5-6: Global - Forecast for Growth Hormone Deficiencies Biosimilars Market (Million US$), 2016 - 2021
Figure 5-7: Global - Chronic and Autoimmune Disorders Biosimilars Market (Million US$), 2014 - 2015
Figure 5-8: Global - Forecast for Chronic and Autoimmune Disorders Biosimilars Market (Million US$), 2016 - 2021
Figure 5-9: Global - Other Applications Biosimilars Market (Million US$), 2014 - 2015
Figure 5-10: Global - Forecast for Other Applications Biosimilars Market (Million US$), 2016 - 2021
Figure 6-1: United States - Biosimilars Market (Million US$), 2014 - 2015
Figure 6-2: United States - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-3: Canada - Biosimilars Market (Million US$), 2014 - 2015
Figure 6-4: Canada - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-5: Argentina - Biosimilars Market (Million US$), 2014 - 2015
Figure 6-6: Argentina - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-7: Germany - Biosimilars Market (Million US$), 2012 - 2015
Figure 6-8: Germany - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-9: France - Biosimilars Market (Million US$), 2012 - 2015
Figure 6-10: France - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-11: Italy - Biosimilars Market (Million US$), 2012 - 2015
Figure 6-12: Italy - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-13: Spain - Biosimilars Market (Million US$), 2012 - 2015
Figure 6-14: Spain - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-15: United Kingdom - Biosimilars Market (Million US$), 2012 - 2015
Figure 6-16: United Kingdom - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-17: China - Biosimilars Market (Million US$), 2013 - 2015
Figure 6-18: China - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-19: Japan - Biosimilars Market (Million US$), 2013 - 2015
Figure 6-20: Japan - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-21: India - Biosimilars Market (Million US$), 2013 - 2015
Figure 6-22: India - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-23: South Korea - Biosimilars Market (Million US$), 2010 - 2015
Figure 6-24: South Korea - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-25: Australia - Biosimilars Market (Million US$), 2014 - 2015
Figure 6-26: Australia - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-27: Brazil - Biosimilars Market (Million US$), 2014 - 2015
Figure 6-28: Brazil - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-29: Mexico - Biosimilars Market (Million US$), 2014 - 2015
Figure 6-30: Mexico - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 6-31: Rest of the World - Biosimilars Market (Million US$), 2013 - 2015
Figure 6-32: Rest of the World - Forecast for Biosimilars Market (Million US$), 2016 - 2021
Figure 7-1: Celltrion Inc. - Annual Revenue (Million US$), 2013 - 2015
Figure 7-2: Dong-A Socio Group - Annual Revenue (Million US$), 2014 - 2015
Figure 7-3: Pfizer Inc. - Annual Revenue (Million US$), 2011 - 2015
Figure 7-4: Intas Pharmaceuticals Ltd. - Annual Revenue (Million US$), 2011 - 2015
Figure 7-5: Intas Pharmaceuticals Ltd. - Major Biosimilars in Pipeline
Figure 7-6: Sandoz International GmbH - Annual Revenue (Million US$), 2012 - 2015
Figure 7-7: Stada Arzneimittel AG - Annual Revenue (Million US$), 2011 - 2015
Figure 7-8: Teva Pharmaceutical Industries Ltd. - Annual Revenue (Million US$), 2011 - 2015
Figure 7-9: Amgen Inc. - Annual Revenue (Million US$), 2011 - 2015
Figure 7-10: Biocon - Annual Revenue (Million US$), 2011 - 2015
Figure 7-11: Mylan - Annual Revenue (Million US$), 2011 - 2015
Figure 7-12: Merck KGaA - Annual Revenue (Million US$), 2013 - 2014
Figure 10-1: Global - Ageing Population & Forecast (Million), 2010 - 2050
Figure 11-1: The EMA Development and Approval Pathway for Biosimilars

  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through Risk Management and Quality by Design
    Published: 01-Mar-2017        Price: US 2995 Onwards        Pages: 117
    Summary Government support for biosimilars is increasing in key geographical markets, given the cost saving opportunities that these products represent for national healthcare budgets. A biosimilar is a bio-therapeutic that is clinically highly similar to an approved innovative product (reference product) in terms of active ingredients, and has no meaningful differences in efficacy and safety. The complexities of manufacturing a biological drug also apply to b......
  • Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2017
    Published: 01-Mar-2017        Price: US 1450 Onwards        Pages: 79
    DelveInsight's, "Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2017" discusses the global insulin biosimilar industry. Report analyzes that Insulin and Insulin Biosimilars holds a future scope and potential in the market. It highlights the market trends, regulatory requirements for US and EU and key domestic players. Report provides an insight on Insulin Biosimilars that are under development for Type 1 and Type 2 Diabetes with an insight on the Epide......
  • Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CMO), Application (Oncology, Blood Disorders) - Global Forecast to 2021
    Published: 05-Jan-2017        Price: US 5650 Onwards        Pages: 152
    The global biosimilars market is expected to reach USD 10.90 billion by 2021 from USD 3.39 billion in 2016, at a CAGR of 26.3%. The biosimilars market is broadly classified into product, manufacturing type, application, and region. On the basis of product, the biosimilars market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins segment is estimated to account for the largest s......
  • 2017-2022 Global Top Countries Biologics and Biosimilars Market Report
    Published: 07-Dec-2016        Price: US 4960 Onwards        Pages: 126
    "This report will be delivered in 2-3 business days after the order is placed." This report studies Biologics and Biosimilars in Global market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, China, Japan, India, Korea, Southeast Asia, Australia, Brazil, Middle East and Africa, focuses on the top Manufacturers in each country, covering - Roche - Amgen - AbbVie - Sanofi-Aventis - Johnson & Johnson......
  • Global Biologics and Biosimilars Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 06-Dec-2016        Price: US 3480 Onwards        Pages: 110
    A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured ......
  • Europe Adalimumab Biosimilar Market Report 2016
    Published: 23-Nov-2016        Price: US 3900 Onwards        Pages: 119
    Notes: Sales, means the sales volume of Adalimumab Biosimilar Revenue, means the sales value of Adalimumab Biosimilar This report studies sales (consumption) of Adalimumab Biosimilar in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - AET BioTech - Amgen - Boehringer Ingelheim......
  • United States Adalimumab Biosimilar Market Report 2016
    Published: 16-Nov-2016        Price: US 3800 Onwards        Pages: 111
    Notes: Sales, means the sales volume of Adalimumab Biosimilar Revenue, means the sales value of Adalimumab Biosimilar This report studies sales (consumption) of Adalimumab Biosimilar in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - AET BioTech - Amgen - Boehringer Ingelheim - Coherus Biosciences - Fujifilm Kyowa Kirin Biologics - LG Life Sciences/Moch......
  • Japan Biosimilar Monoclonal Antibodies Market Report 2016
    Published: 14-Nov-2016        Price: US 3400 Onwards        Pages: 119
    Notes: Sales, means the sales volume of Biosimilar Monoclonal Antibodies Revenue, means the sales value of Biosimilar Monoclonal Antibodies This report studies sales (consumption) of Biosimilar Monoclonal Antibodies in Japan market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Celltrion - Boehringer Ingelheim - Dr Reddy's - Sandoz - Zydus - Samsung - Amgen -......
  • Japan Biosimilars Market Report 2016
    Published: 14-Nov-2016        Price: US 3400 Onwards        Pages: 122
    Notes: Sales, means the sales volume of Biosimilars Revenue, means the sales value of Biosimilars This report studies sales (consumption) of Biosimilars in Japan market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Roche - Amgen - AbbVie - Sanofi-Aventis - Johnson & Johnson - Pfizer - Novo Nordisk - Eli Lilly - Novartis - Merck - 3sbio......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs